Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF) (PROMISE-AF)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03906799 |
|
Recruitment Status :
Completed
First Posted : April 8, 2019
Last Update Posted : September 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Atrial Fibrillation | Drug: OMT-28 Drug: Placebo | Phase 2 |
This is a randomized, double-blind, dose-finding, placebo-controlled, parallel group, multicenter, phase II study to evaluate the efficacy, safety, and popPK of three different doses of OMT-28 given once daily versus placebo in patients with persistent AF. At randomization, the duration of the current episode of persistent AF must be shown to be greater than 7 days and not greater than 3 months, as confirmed by two ECGs (one ECG must be a 12-lead ECG) and further patient enquiry (including doctor visits, hospital admissions, symptom onset, etc.).
A sample size re-evaluation will be performed to avoid an underpowered study because of imprecise estimates for the study population or overoptimistic parameter estimates. Therefore, an interim analysis will re-evaluate sample size assumptions after approximately 15 patients per study arm (~50 % of planned sample) have completed the treatment phase (Visit 8) of the study. Predefined rules will govern the decision for adjustment of sample size.
Patients will be monitored for cardiac events throughout the study using an Implantable Cardiac Monitor (ICM). Safety will be monitored throughout the study. Blood samples will be collected in pre-specified windows for popPK analysis and at pre-specified timepoints for PK/PD analysis. Patients will be provided with a diary to record timing of drug administration and clinical symptoms while not on site. Diaries will be reviewed and checked for compliance at each non-resident visit to the clinical site.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 136 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Placebo-controlled, Double-blind, Randomized, Dose-finding Phase II Study on OMT-28 in MaIntenance of Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (PROMISE-AF) |
| Actual Study Start Date : | March 19, 2019 |
| Actual Primary Completion Date : | November 20, 2019 |
| Actual Study Completion Date : | March 20, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Low OMT-28
Verum, low OMT-28
|
Drug: OMT-28
1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days). |
|
Experimental: Middle OMT-28
Verum, middle OMT-28
|
Drug: OMT-28
1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days). |
|
Experimental: High OMT-28
Verum, high OMT-28
|
Drug: OMT-28
1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days). |
|
Placebo Comparator: Placebo
Placebo
|
Drug: Placebo
1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days). |
- Assessment of AF Burden After OMT-28 Administration [ Time Frame: Up to 4.5 months ]To assess the AF burden, based on data collected via the implantable cardiac monitor BioMonitor 2-AF, of three different doses of OMT-28 administered once daily versus placebo in the maintenance of normal sinus rhythm after electrical direct current cardioversion (DCC) in patients with persistent AF
- Incidence of Treatment-Emergent Adverse Events [ Time Frame: Up to 4.5 months ]To assess the incidence of treatment-emergent Adverse Events of three different doses of OMT-28 administered once daily versus placebo after electrical DCC in patients with persistent AF.
- Assessment of Pharmacokinetic (PK) Parameters of OMT-28 - AUC [ Time Frame: Up to 3.5 months ]To assess the pharmacokinetic (PK) parameter AUC of OMT-28 administered once daily in patients with persistent AF, by means of population PK (popPK) analysis.
- Assessment of Pharmacokinetic (PK) Parameters of OMT-28 - Cmax [ Time Frame: Up to 3.5 months ]To assess the pharmacokinetic (PK) parameter Cmax of OMT-28 administered once daily in patients with persistent AF, by means of population PK (popPK) analysis.
- Concentration of NT-proBNP [ Time Frame: Up to 3.5 months ]To assess the concentration of the exploratory, pharmacodynamic (PD) parameter NT-proBNP after once-daily administration of OMT-28 or placebo in patients with persistent AF.
- Concentration of GDF-15 [ Time Frame: Up to 3.5 months ]To assess the concentration of the exploratory, pharmacodynamic (PD) parameter GDF-15 after once-daily administration of OMT-28 or placebo in patients with persistent AF.
- Concentration of MMP-9 [ Time Frame: Up to 3.5 months ]To assess the concentration of the exploratory, pharmacodynamic (PD) parameter MMP-9 after once-daily administration of OMT-28 or placebo in patients with persistent AF.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males or females between 18 and 85 years of age.
- Patients with persistent AF for > 7 days but ≤ 3 months suitable for electrical DCC.
- Male patients must be surgically sterile for at least 90 days or will be required to use a male condom with spermicide, and will refrain from donating sperm from the time of the first dose until 90 days after the last dose of study medication.
- Females of childbearing potential (postmenarchal, not surgically sterile, premenopausal) will agree to follow contraception requirements from the time of signing the Informed Consent Form (ICF) until 90 days after the last administration of study drug.
- Willing and able to give written informed consent before any study-related procedure.
- Willing and able to attend all the visits scheduled in the study.
Main Exclusion Criteria:
- Patients with known concurrent temporary secondary causes of AF
- Patients that have undergone surgical or catheter ablation for AF or atrial flutter.
- Patients with an existing cardiac treatment device, pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy.
- Patients with a history of ECG abnormalities that, in the opinion of the investigator (or designee), render the patient unsuitable for the study.
- Patients with congestive heart failure (NYHA class III and IV).
- Patients with left atrium size ≥ 55 mm.
- Patients with left ventricular ejection fraction ≤ 40 %.
- Known presence of a thrombus in the left atrial appendage, left atrium, left ventricle, aorta, or intracardial mass.
- Patients with moderate or severe mitral stenosis, mitral valve rheumatic disease, unresected atrial myxoma, or a mechanical heart valve and/or other conditions, such as pulmonary embolism, considered to be formal indication for conventional anticoagulation.
- Patients with any acute coronary event, stroke, or percutaneous coronary intervention within 6 months prior to randomization or who are receiving dual antiplatelet therapy.
- Uncontrolled/therapy-resistant bradycardia and/or uncontrolled/therapy-resistant hypertension within a 3-month period prior to randomization.
- Patients having more than two DCCs in the last 6 months. Any unsuccessful pharmacological and/or electrical cardioversion (within prior 3 months).
- Patients with signs of bleeding or conditions associated with a high risk of bleeding.
- Patients taking antiarrhythmic agents within 3 days of planned randomization will be excluded.
- Patients concurrently participating in another study or unable to communicate.
- Patients with active cancer, chronic kidney disease or intercurrent illness.
- Pregnant or breastfeeding women.
- Patients taking concomitant medication.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03906799
Show 25 study locations
| Study Director: | Alexander Gebauer, Dr.med. | Managing Director |
Publications:
| Responsible Party: | Omeicos Therapeutics GmbH |
| ClinicalTrials.gov Identifier: | NCT03906799 |
| Other Study ID Numbers: |
OMT28-C0201 |
| First Posted: | April 8, 2019 Key Record Dates |
| Last Update Posted: | September 9, 2021 |
| Last Verified: | March 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Atrial Fibrillation Electrical Cardioversion Dose-finding |
|
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |